2007
Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model
Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model. Journal Of Allergy And Clinical Immunology 2007, 120: 1146-1152. PMID: 17904628, PMCID: PMC3476046, DOI: 10.1016/j.jaci.2007.07.055.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCost-effectiveness ratioSevere asthmaEvent ratesSevere allergic asthmaQuality-adjusted monthsAllergic asthmaMost patientsAlternative medicationsHigher acquisition costUS FoodAsthmaDrug AdministrationLife yearsPatientsIncremental costDisease managementOmalizumabCost-effective optionTreatmentAcquisition costsEconomic outcomesCorticosteroidsMedicationsClinicians
2002
AIDS Drug Assistance Programs: Highlighting Inequities in Human Immunodeficiency Virus–Infection Health Care in the United States
Walensky RP, Paltiel AD, Freedberg KA. AIDS Drug Assistance Programs: Highlighting Inequities in Human Immunodeficiency Virus–Infection Health Care in the United States. Clinical Infectious Diseases 2002, 35: 606-610. PMID: 12173137, DOI: 10.1086/341903.Peer-Reviewed Original ResearchConceptsEffective antiretroviral therapyHuman immunodeficiency virusDrug Assistance ProgramsCost-effectiveness analysisAntiretroviral therapyHIV careMedication costsImmunodeficiency virusOutpatient arenaDisease outcomePatient's placePrivate health insuranceHealth careHealth insurancePatientsAIDSCareUnited StatesMedicationsHIVInpatientsTherapyMedicaid